Abivax CEO suggests no urgency for deal-making ahead of key trial readout
Source: SeekingAlpha
2026-03-24 13:04:05 ET
More on Abivax
- Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement
- Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
- Abivax reports FY results
- Abivax pares gain after denying AstraZeneca speculation
- Seeking Alpha’s Quant Rating on Abivax
Read the full article on Seeking Alpha
For further details see:
Abivax CEO suggests no urgency for deal-making ahead of key trial readout
Abivax SA
NASDAQ: ABVX
ABVX Trading
3.27% G/L:
$99.835 Last:
1,550,008 Volume:
$105.18 Open:
ABVX Latest News
June 03, 2026 08:53:00 pm
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 02, 2026 09:20:00 pm
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
ABVX Stock Data
$9,359,969,582
53,161,297
N/A
64
N/A
Biotechnology & Life Sciences
Healthcare
FR
Paris
